Polyethylene glycol 4000
As of the edition of 20 October 2026, Polyethylene glycol 4000 is a small molecule: marketed, first approved in 1987 (FR).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2018
- Kind
- Small molecule
- Brand name
- Fortrans
- First approved
- 7 July 1987 (FR)
- Approvals on record
- 3 in 3 regions
- Holder of the most recent approval
- EA Pharma; 3 holders in all
- Registered trials
- 8, 1 stopped early
- Disease areas
- Digestive system; Cancer; Inherited and neonatal; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 1 | 1 | 0 |
| Phase 2 | 1 | 0 | 0 | 1 |
| Phase 3 | 1 | 1 | 0 | 0 |
| Phase 4 | 4 | 4 | 0 | 0 |
| All trials | 8 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| EA Pharma | Applicant | 2018 to now |